News Center

Luye Pharma’s Rykindo® (Risperidone Microspheres for Injection (II)) Included in the 2021 Chinese National Reimbursement Drug List

2021 / 12 / 03 Publisher:Luye Life Sciences Group

Luye Pharma Group today announced that Rykindo® (Risperidone Microspheres for Injection (II)), its new anti-schizophrenia drug, has been put on the latest edition of the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA). This drug, an intramuscular injection administered once every two weeks, is used to treat clear positive or negative symptoms of acute and chronic schizophrenia as well as various other psychotic disorders. It can alleviate the affective symptoms associated with schizophrenia.

Rykindo® is an extended release microspheres injection developed on Luye Pharma's globally leading microsphere platform. The drug is China's first locally developed and IP-protected innovative microsphere formulation, which is currently being registered globally. It is also China's first locally developed Generation II long-acting antipsychotic injection. Rykindo®'s coverage by the NRDL will bring new hope to about 10 million schizophrenia patients in China.

Yang Rongbing, President of Luye Pharma Group, said: “The fact that Rykindo® was able to be covered by the NRDL in Year One after its launch demonstrates that the healthcare security authority and various experts have recognized the drug's clinical value, patient benefit, and innovativeness. We’ll continue to put patients first and leverage our knowhow and portfolio in the central nervous system therapeutic area to reduce patients’ financial burden and increase drug accessibility for them. We hope that more patients will be able to benefit from this high-quality and innovative product.”

For its clear superiority in treatment, Rykindo® was granted a priority review designation by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in December 2019, and was approved for launch by the NMPA on January 12, 2021. In addition to its approval in China, Rykindo® is also being applied for registration globally. It has entered the new drug application stage in the U.S., and is undergoing clinical trials in Europe.


Related hot spots